Arcus Biosciences (RCUS) Competitors $9.60 -0.01 (-0.10%) As of 02:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RCUS vs. SRRK, ACAD, PTCT, ZLAB, ACLX, VKTX, SWTX, AAPG, PTGX, and MLTXShould you be buying Arcus Biosciences stock or one of its competitors? The main competitors of Arcus Biosciences include Scholar Rock (SRRK), ACADIA Pharmaceuticals (ACAD), PTC Therapeutics (PTCT), Zai Lab (ZLAB), Arcellx (ACLX), Viking Therapeutics (VKTX), SpringWorks Therapeutics (SWTX), Ascentage Pharma Group International (AAPG), Protagonist Therapeutics (PTGX), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry. Arcus Biosciences vs. Its Competitors Scholar Rock ACADIA Pharmaceuticals PTC Therapeutics Zai Lab Arcellx Viking Therapeutics SpringWorks Therapeutics Ascentage Pharma Group International Protagonist Therapeutics MoonLake Immunotherapeutics Scholar Rock (NASDAQ:SRRK) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk. Does the media favor SRRK or RCUS? In the previous week, Scholar Rock had 1 more articles in the media than Arcus Biosciences. MarketBeat recorded 4 mentions for Scholar Rock and 3 mentions for Arcus Biosciences. Scholar Rock's average media sentiment score of 1.40 beat Arcus Biosciences' score of 0.39 indicating that Scholar Rock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcus Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation and earnings, SRRK or RCUS? Scholar Rock has higher earnings, but lower revenue than Arcus Biosciences. Scholar Rock is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScholar Rock$33.19M110.14-$246.29M-$2.53-15.22Arcus Biosciences$258M3.94-$283M-$4.19-2.29 Do analysts rate SRRK or RCUS? Scholar Rock currently has a consensus target price of $44.14, indicating a potential upside of 14.66%. Arcus Biosciences has a consensus target price of $21.29, indicating a potential upside of 121.73%. Given Arcus Biosciences' higher probable upside, analysts plainly believe Arcus Biosciences is more favorable than Scholar Rock.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scholar Rock 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22Arcus Biosciences 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.89 Do insiders and institutionals believe in SRRK or RCUS? 91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 13.3% of Scholar Rock shares are held by company insiders. Comparatively, 9.6% of Arcus Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is SRRK or RCUS more profitable? Scholar Rock has a net margin of 0.00% compared to Arcus Biosciences' net margin of -258.94%. Arcus Biosciences' return on equity of -70.58% beat Scholar Rock's return on equity.Company Net Margins Return on Equity Return on Assets Scholar RockN/A -118.22% -82.01% Arcus Biosciences -258.94%-70.58%-32.97% Which has more volatility and risk, SRRK or RCUS? Scholar Rock has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. SummaryScholar Rock beats Arcus Biosciences on 10 of the 17 factors compared between the two stocks. Get Arcus Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RCUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RCUS vs. The Competition Export to ExcelMetricArcus BiosciencesMED IndustryMedical SectorNYSE ExchangeMarket Cap$1.02B$3.06B$5.61B$20.89BDividend YieldN/A2.39%4.71%3.60%P/E Ratio-2.2921.5127.9028.01Price / Sales3.94205.32392.4668.85Price / CashN/A42.5736.3223.29Price / Book1.818.338.394.56Net Income-$283M-$55.06M$3.25B$993.24M7 Day Performance-1.49%-2.37%-1.61%-1.58%1 Month Performance17.50%15.92%9.08%3.09%1 Year Performance-39.16%5.53%35.49%9.26% Arcus Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RCUSArcus Biosciences1.5195 of 5 stars$9.60-0.1%$21.29+121.7%-39.4%$1.02B$258M-2.29500Upcoming EarningsGap UpSRRKScholar Rock3.3055 of 5 stars$41.12+1.0%$42.67+3.8%+307.3%$3.87B$33.19M-16.25140News CoveragePositive NewsUpcoming EarningsAnalyst ForecastGap UpACADACADIA Pharmaceuticals4.0988 of 5 stars$22.28-1.2%$27.88+25.1%+20.7%$3.78B$957.80M16.26510News CoverageUpcoming EarningsAnalyst RevisionPTCTPTC Therapeutics4.4581 of 5 stars$47.86+0.5%$65.00+35.8%+51.6%$3.78B$806.78M7.351,410Trending NewsAnalyst ForecastAnalyst RevisionZLABZai Lab3.0796 of 5 stars$34.66+3.2%$54.28+56.6%+115.6%$3.73B$398.99M-13.921,869Gap DownACLXArcellx2.456 of 5 stars$69.39+2.7%$111.23+60.3%+12.7%$3.72B$107.94M-23.2180Positive NewsGap UpVKTXViking Therapeutics4.4565 of 5 stars$31.94-0.2%$87.15+172.9%-46.3%$3.60BN/A-27.7720Trending NewsEarnings ReportAnalyst RevisionSWTXSpringWorks Therapeutics0.6383 of 5 stars$46.99flat$52.57+11.9%N/A$3.54B$191.59M-13.78230Upcoming EarningsAAPGAscentage Pharma Group InternationalN/A$39.71-1.7%N/AN/A$3.52B$134.35M0.00600Gap DownPTGXProtagonist Therapeutics1.3717 of 5 stars$55.22-0.5%$66.10+19.7%+41.7%$3.44B$434.43M73.63120News CoverageUpcoming EarningsInsider TradeMLTXMoonLake Immunotherapeutics2.8288 of 5 stars$53.57+0.9%$74.50+39.1%+21.4%$3.40BN/A-23.292News CoverageUpcoming EarningsAnalyst Upgrade Related Companies and Tools Related Companies Scholar Rock Competitors ACADIA Pharmaceuticals Competitors PTC Therapeutics Competitors Zai Lab Competitors Arcellx Competitors Viking Therapeutics Competitors SpringWorks Therapeutics Competitors Ascentage Pharma Group International Competitors Protagonist Therapeutics Competitors MoonLake Immunotherapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:RCUS) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredDrone Company Secures Major Defense Contract Amid Sweeping Policy ShiftOn July 10th, the White House and DoD announced a sweeping new directive to fast-track U.S. drone dominance. ...The Tomorrow Investor | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredOne stock to replace Nvidia"I said 'SELL' before this stock dropped 90%. Today, I'm shouting 'BUY NOW' before it's too late." In 2000,...InvestorPlace | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thNew China tariffs hit August 12th—and Wall Street’s already moving. Banks and billionaires are quietly shif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcus Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
